130 related articles for article (PubMed ID: 38287534)
41. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
42. Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series.
Lewis DJ; Byekova YA; Emge DA; Duvic M
J Dermatolog Treat; 2017 Sep; 28(6):567-569. PubMed ID: 28635518
[TBL] [Abstract][Full Text] [Related]
43. Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: Real-world experience from post-marketing surveillance.
Hamada T; Morita A; Suga H; Boki H; Fujimura T; Hirai Y; Shimauchi T; Tateishi C; Kiyohara E; Muto I; Nakajima H; Abe R; Fujii K; Nishigori C; Nakano E; Yonekura K; Funakoshi T; Amano M; Miyagaki T; Makita N; Manaka K; Shimoyama Y; Sugaya M
J Dermatol; 2022 Feb; 49(2):253-262. PubMed ID: 34658060
[TBL] [Abstract][Full Text] [Related]
44. Epidemiology and prognostic factors of 114 patients with mycosis fungoides in a Moroccan cohort: a 29-year review.
Titou H; Bouhamidi A
Clin Exp Med; 2023 Nov; 23(7):3751-3758. PubMed ID: 37029872
[TBL] [Abstract][Full Text] [Related]
45. Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways.
Pérez C; Mondéjar R; García-Díaz N; Cereceda L; León A; Montes S; Durán Vian C; Pérez Paredes MG; González-Morán A; Alegre de Miguel V; Sanz Anquela JM; Frias J; Limeres MA; González LM; Martín Dávila F; Beltrán M; Mollejo M; Méndez JR; González MA; González García J; López R; Gómez A; Izquierdo F; Ramos R; Camacho C; Rodriguez-Pinilla SM; Martínez N; Vaqué JP; Ortiz-Romero PL; Piris MA
Br J Dermatol; 2020 Jan; 182(1):147-155. PubMed ID: 31049933
[TBL] [Abstract][Full Text] [Related]
46. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.
Ralfkiaer U; Lindahl LM; Litman T; Gjerdrum LM; Ahler CB; Gniadecki R; Marstrand T; Fredholm S; Iversen L; Wasik MA; Bonefeld CM; Geisler C; Krejsgaard T; Glue C; Røpke MA; Woetmann A; Skov L; Grønbæk K; Odum N
Anticancer Res; 2014 Dec; 34(12):7207-17. PubMed ID: 25503151
[TBL] [Abstract][Full Text] [Related]
47. The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data.
Amitay-Laish I; Guenova E; Ortiz-Romero PL; Vico-Alonso C; Rozati S; Geskin LJ; Nikolaou V; Papadavid E; Barzilai A; Pavlovsky L; Didkovsky E; Naveh HP; Akilov OE; Hodak E
Acta Derm Venereol; 2020 Sep; 100(16):adv00277. PubMed ID: 32965506
[TBL] [Abstract][Full Text] [Related]
48. Identification of a Distinct miRNA Regulatory Network in the Tumor Microenvironment of Transformed Mycosis Fungoides.
Di Raimondo C; Han Z; Su C; Wu X; Qin H; Sanchez JF; Yuan YC; Martinez X; Abdulla F; Zain J; Chen CW; Rosen ST; Querfeld C
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34831008
[TBL] [Abstract][Full Text] [Related]
49. Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T-cell lymphomas: a case series.
Teoli M; Mandel VD; Franceschini C; Saraceni PL; Cicini MP; Ardigò M
Eur Rev Med Pharmacol Sci; 2022 Nov; 26(21):8118-8128. PubMed ID: 36394762
[TBL] [Abstract][Full Text] [Related]
50. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells.
Zhang C; Ni X; Konopleva M; Andreeff M; Duvic M
J Invest Dermatol; 2004 Aug; 123(2):380-7. PubMed ID: 15245439
[TBL] [Abstract][Full Text] [Related]
51. [Treatment of mycosis fungoides with PUVA and bexarotene].
Ortiz-Romero PL; Sánchez-Largo ME; Sanz H; García-Romero D; Rosales B; Valverde R; Arrue I; Polo I; Ruiz D; Fernández-Herrera J; Vanaclocha F
Actas Dermosifiliogr; 2006 Jun; 97(5):311-8. PubMed ID: 16956562
[TBL] [Abstract][Full Text] [Related]
52. Multidisciplinary Approach to the Diagnosis and Therapy of Mycosis Fungoides.
Vitiello P; Sagnelli C; Ronchi A; Franco R; Caccavale S; Mottola M; Pastore F; Argenziano G; Creta M; Calogero A; Fiorelli A; Casale B; Sica A
Healthcare (Basel); 2023 Feb; 11(4):. PubMed ID: 36833148
[TBL] [Abstract][Full Text] [Related]
53. Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma.
Gaydosik AM; Queen DS; Trager MH; Akilov OE; Geskin LJ; Fuschiotti P
Blood; 2020 Oct; 136(15):1748-1759. PubMed ID: 32438399
[TBL] [Abstract][Full Text] [Related]
54. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas.
Quaglino P; Pimpinelli N; Berti E; Calzavara-Pinton P; Alfonso Lombardo G; Rupoli S; Alaibac M; Bottoni U; Carbone A; Fava P; Fimiani M; Mamusa AM; Titli S; Zinzani PL; Bernengo MG;
Cancer; 2012 Dec; 118(23):5830-9. PubMed ID: 22674564
[TBL] [Abstract][Full Text] [Related]
55. Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Hedbrant A; Wijkander J; Seidal T; Delbro D; Erlandsson A
Tumour Biol; 2015 Nov; 36(11):8715-25. PubMed ID: 26050228
[TBL] [Abstract][Full Text] [Related]
56. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.
Papadavid E; Antoniou C; Nikolaou V; Siakantaris M; Vassilakopoulos TP; Stratigos A; Stavrianeas N; Katsambas A
Am J Clin Dermatol; 2008; 9(3):169-73. PubMed ID: 18429646
[TBL] [Abstract][Full Text] [Related]
57. Expression dynamics of CXCL12 and CXCR4 during the progression of mycosis fungoides.
Daggett RN; Kurata M; Abe S; Onishi I; Miura K; Sawada Y; Tanizawa T; Kitagawa M
Br J Dermatol; 2014 Oct; 171(4):722-31. PubMed ID: 24725174
[TBL] [Abstract][Full Text] [Related]
58. Expression of CXCR4 and CXCL12 and their correlations to the cell proliferation and angiogenesis in mycosis fungoides.
Maj J; Jankowska-Konsur AM; Hałoń A; Woźniak Z; Plomer-Niezgoda E; Reich A
Postepy Dermatol Alergol; 2015 Dec; 32(6):437-42. PubMed ID: 26755907
[TBL] [Abstract][Full Text] [Related]
59. Rapidly progressive tumor stage mycosis fungoides: A case report from Syria.
Melhem Y; Hussein Al-Janabi M; Mansour M; Suleman H; Al-Shehabi Z
Ann Med Surg (Lond); 2022 Dec; 84():104834. PubMed ID: 36582887
[TBL] [Abstract][Full Text] [Related]
60. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
